Meet the MedCity Media Team

And take 2 minutes to help us make better for you.

Every year, we ask you to tell us a little about yourself (anonymously) to help us create better, more relevant content and features for you. We consider every response and very much appreciate you taking the time to assist us.

Please click the button above to open a simple, multiple choice survey that should only take 2 minutes to complete.

Thank you,

The MedCity Media Team

Adeona Pharmaceuticals pulls in $1M equity investment

10:51 am by | 0 Comments

Adeona Pharmaceuticals (AMEX: AEN) has received a $1 million equity investment from a Florida private equity firm as the drug developer looks to bring a drug to market for the first time.

The funding comes from the sale of 1.2 million shares to Seaside 88 LP, according to a statement from Adeona.

Any source of cash is welcome for Adeona–at least until it gets a drug on the market that can start generating sales. In its most recent quarter, the company (pdf) lost nearly $1.1 million, about the same as the like quarter last year.

Adeona is trying to push across the finish line its Zinthionein ZC, an oral drug for Alzheimer’s disease and mild cognitive impairment. The company announced that it has completed 75 percent of the enrollment for the second part of a 60-patient study of the drug.


We should know more about the trial’s outcome in the first quarter of 2011, when Adeona plans to announce its results. If the results are positive, the drug could be on the market sometime next year, according to the statement.

Adeona is developing Zinthionein ZC as a prescription medical food that aims to alleviate zinc deficiencies in patients with Alzheimer’s disease.

The company has several other drugs in development, including Trimesta, a multiple sclerosis treatment that’s in (pdf) the midst of clinical trials.

In May, Adeona (pdf) struck a licensing deal with a Swedish pharmaceuticals firm, Meda AB, for its patents related to a treatment for fibromyalgia. The deal called for an upfront payment of $2.5 million to Adeona, and could be worth up to $17.5 million plus royalties to the Ann Arbor drug developer.

Adeona hired a new CEO, James Kuo, in May.

Copyright 2014 MedCity News. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Brandon Glenn

By Brandon Glenn MedCity News

Brandon Glenn is the Ohio bureau chief for MedCity News.
More posts by Author


Hear the latest news first

Get our daily newsletter or follow us.